XM does not provide services to residents of the United States of America.

Repligen falls on CEO transition

<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BUZZ-Repligen falls on CEO transition</title></head><body>

** Shares of biotech co Repligen Corp RGEN.O fall 9.8% to $128.83

** Co says board has approved the planned transition of Tony Hunt from CEO to executive chair, effective Sept. 1

** Says its board has appointed Olivier Loeillot, who joined RGEN in 2023 as president and chief commercial officer, as CEO to succeed Tony Hunt, also effective from Sept. 1

** Hunt has served as RGEN's CEO since May 2015

** This announcement is not a complete surprise, albeit a bit sooner than expected, says Stephens analyst Jacob Johnson

** "Still, Tony was synonymous with RGEN and today may reveal how large the Tony Hunt premium was," Johnson adds

** Including session moves, stock down 28% YTD

Reporting by Sneha S K in Bengaluru


Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.